Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Sales (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Return on Sales for 11 consecutive years, with 0.09% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 5.0% year-over-year to 0.09%, compared with a TTM value of 0.16% through Sep 2025, down 3.0%, and an annual FY2024 reading of 0.15%, up 4.0% over the prior year.
  • Return on Sales was 0.09% for Q3 2025 at Sunshine Biopharma, up from 0.19% in the prior quarter.
  • Across five years, Return on Sales topped out at 7.84% in Q4 2021 and bottomed at 154.4% in Q1 2021.
  • Average Return on Sales over 5 years is 16.5%, with a median of 0.19% recorded in 2025.
  • The sharpest move saw Return on Sales crashed -15434bps in 2021, then skyrocketed 14432bps in 2022.
  • Year by year, Return on Sales stood at 7.84% in 2021, then plummeted by -176bps to 5.97% in 2022, then skyrocketed by 97bps to 0.16% in 2023, then crashed by -38bps to 0.22% in 2024, then soared by 58bps to 0.09% in 2025.
  • Business Quant data shows Return on Sales for SBFM at 0.09% in Q3 2025, 0.19% in Q2 2025, and 0.13% in Q1 2025.